English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Benign and malignant prostatic diseases are generallywell-known in the world. Accordingly, this research is planned to assess the immunohistochemicalanalysis of CD133 and CD166 in the prostatic epithelium in samples of benign prostatic hyperplasia (BPH) and normal looking epithelium around prostatic adenocarcinoma samples (PCa) and to explore the opportunity of malignant alterations in benign tissue. The prostate samples were divided into 2 groups; 50 BPH samples, and 50 normally looking tissue surrounding prostatic carcinoma samples (NPCA). The samples were treated for immunohistochemicalexamination of CD133 and CD166. Over expression of CD133 appeared in the BPH group which was statistically significant as compared to NPCA group. Conversely, over expression of CD166 stem cell marker in NPCA group than BPH group as it was significant statistically. CD166 is a stem cell marker for tissue tumorigenicity, while the positive expression of CD133 is not of value for cancer initiation.

CD133 and CD166 as stem cell markers for predicting the possibility of developing prostatic cancer in cases of benign prostatic hyperplasia